// STATE LEGISLATION TRACKER

Rhode Island HB 7424 — AN ACT RELATING TO BUSINESSES AND PROFESSIONS -- COLLABORATIVE PHARMACY PRACTICE

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Rhode Island
Bill: HB 7424
Session: 2026
Filed: 2026-01-30
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

This bill appears to deal with collaborative pharmacy practice, which generally means pharmacists working under agreements with prescribers. Based only on the title and lack of recorded actions, it does not appear to directly regulate peptides, compounding, telehealth, naturopathic practice, NP scope, controlled substances, or prescription monitoring.

Key Points

No clear direct effect on compounded peptide access
No clear change to off-label peptide prescribing
No clear 503A or 503B compounding rule change
Could matter only if pharmacy collaboration rules later touch prescribing workflows

What to Watch For

Note Watch for bill text or amendments that define what pharmacists may manage under collaborative agreements.

Note Check whether later versions mention prescriptive authority, injections, compounding, or controlled substances.

Note If no actions remain recorded, this may have little practical effect this session.

Where the Bill Stands

OpenStates lists no recorded actions for Rhode Island HB7424, so its procedural status cannot be confirmed from the provided record.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws